CIENCIASMEDICASNEWS: Fecal inmunochemical test accuracy in f

lunes, 15 de julio de 2013

Fecal inmunochemical test accuracy in f - PubMed Mobile

Fecal inmunochemical test accuracy in familial risk colorectal cancer screening.

Authors

Castro I, et al. Show all

Journal

Int J Cancer. 2013 Jul 1. doi: 10.1002/ijc.28353. [Epub ahead of print]

Affiliation

Department of Gastroenterology, Complexo Hospitalario Universitario de Ourense. Ourense, Spain.

Abstract

There is little information on fecal immunochemical test (FIT) in familial risk colorectal cancer (CRC) screening. Our study assesses FIT accuracy, number needed to scope (NNS) and cost to detect a CRC and an advanced neoplasia (AN) in this setting. We performed a multicentric, prospective, double blind study of diagnostic tests on individuals with first-degree relatives (FDR) with CRC submitted to screening colonoscopy. Two stool samples were collected and fecal hemoglobin in the first sample (FIT1) and the highest in both samples (FITmax) were determined. Areas under the curve (AUC) for CRC and AN, as well as the best FIT1 and FITmax cut-off value for CRC were determined. At this threshold, NNS and the cost per lesion detected were calculated. 595 individuals were included (one FDR > 60 years, 413; two FDR or one ≤60 years, 182). AN and CRC were found in 64 (10.8%) and 6 (1%) patients. For CRC diagnosis, FIT1 AUC was 0.96 (95% CI 0.95-0.98) and FITmax AUC was 0.95 (95% CI 0.93-0.97). For AN diagnosis, FIT1 and FITmax AUC was 0.74 (95% CI 0.66-0.82). The best cut-off point for CRC was 115. At this threshold, the NNS to detect a CRC were 5.67 and 7.67, and the cost per CRC was 1,064€ and 1,591.33€ on FIT1 and FITmax strategies respectively. FIT shows high accuracy to detect CRC in familial CRC screening. Performing two tests does not improve diagnostic accuracy, but increases cost and NNS to detect a lesion. © 2013 Wiley Periodicals, Inc.